Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1190399 | 0.68 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL4496620 | 0.61 | — | — | |
| SCHEMBL20833461 | 0.59 | MAPT (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL20833494 | 0.59 | SLC6A4 (0.38) | SLC6A4SLC6A3 | |
| SCHEMBL20208763 | 0.59 | MAPT (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL20209452 | 0.59 | MAPT (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL6288977 | 0.57 | MAPT (0.41) | SLC6A4SLC6A3 | |
| SCHEMBL20833049 | 0.57 | MAPT (0.41) | SLC6A4SLC6A3 | |
| SCHEMBL10555948 | 0.57 | SLC6A4 (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL4475990 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799772-B2 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-21 | — | — | US | disclosed |
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | JANSSEN-CILAG (FR) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | NR1H3, NR1H2, ERBB2 | SLC6A4 3675/4885SLC6A3 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.